This week CVS Health launched Cordavis, a wholly owned subsidiary that will work with manufacturers to commercialize and/or co-produce biosimilar products for the U.S. pharmaceutical market.
The Cordavis products will be FDA approved, CVS said, adding that the move should help ensure a more consistent long-term supply of affordable biosimilars.
WHAT’S THE IMPACT
